乳がんADC治療薬の世界市場に関する洞察、2031年までの予測

当レポートは、乳がんADC治療薬 (Breast Cancer ADC Drugs) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

• 乳がんADC治療薬の製品概要
• 市場：タイプ別
  • 世界の乳がんADC治療薬の市場規模成長率：タイプ別, 2020 VS 2024 VS 2031
  • First-generation ADC Drugs
  • Second-generation ADC Drugs
  • Third-generation ADC Drugs
• 市場：用途別
  • 世界の乳がんADC治療薬の市場規模成長率：用途別, 2020 VS 2024 VS 2031
  • Non-invasive Cancer
  • Invasive Cancer
• 前提条件と制限
• 調査目的
• 対象期間

第2章 レポート概要

• 世界の乳がんADC治療薬の収益 推定および予測 2020-2031
• 世界の収益：地域別
  • 世界の乳がんADC治療薬 収益：地域別: 2020 VS 2024 VS 2031
  • 世界の乳がんADC治療薬 収益：地域別 (2020-2031)
  • 世界の乳がんADC治療薬の収益市場シェア 地域別 (2020-2031)
• 世界の乳がんADC治療薬 売上予測・予想 2020-2031
• 世界の販売：地域別
  • 世界の乳がんADC治療薬 販売：地域別: 2020 VS 2024 VS 2031
  • 世界の乳がんADC治療薬 販売：地域別 (2020-2031)
  • 世界の乳がんADC治療薬の販売市場シェア 地域別 (2020-2031)
• 米国・カナダ
• 欧州
• 中国
• アジア（中国を除く）
• 中東, アフリカ ・ラテンアメリカ

第3章 競合：企業別

• 世界の販売：企業別
  • 世界の乳がんADC治療薬 販売：企業別 (2020-2025)
  • 世界の乳がんADC治療薬の販売市場シェア：企業別 (2020-2025)
  • 世界の上位10・上位5企業： 乳がんADC治療薬 2024年
• 世界の収益：企業別
  • 世界の乳がんADC治療薬 収益：企業別 (2020-2025)
  • 世界の乳がんADC治療薬の収益市場シェア：企業別 (2020-2025)
  • 世界の上位10・上位5企業： 乳がんADC治療薬 収益 2024年
• 世界の主要企業 乳がんADC治療薬, 業界ランキング, 2023 VS 2024
• 世界の乳がんADC治療薬の販売価格：企業別 (2020-2025)
• 競合情勢の分析
  • 企業の市場集中度 (CR5 and HHI)
  • 世界の乳がんADC治療薬の市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
• 世界の主要メーカー 乳がんADC治療薬, 製造拠点分布と本社
• 世界の主要メーカー 乳がんADC治療薬, 提供製品と用途
• 世界の主要メーカー 乳がんADC治療薬, 業界参入時期
• M&A, 拡張計画

第4章 市場規模：タイプ別

• 世界の販売：タイプ別
  • 世界の乳がんADC治療薬の販売実績：タイプ別 (2020-2025)
  • 世界の乳がんADC治療薬の販売予測：タイプ別 (2026-2031)
  • 世界の乳がんADC治療薬の販売市場シェア：タイプ別 (2020-2031)
• 世界の収益：タイプ別
  • 世界の乳がんADC治療薬の収益実績：タイプ別 (2020-2025)
  • 世界の乳がんADC治療薬の収益予測：タイプ別 (2026-2031)
  • 世界の乳がんADC治療薬の収益市場シェア：タイプ別 (2020-2031)
• 世界の価格：タイプ別
  • 世界の乳がんADC治療薬 価格：タイプ別 (2020-2025)
  • 世界の乳がんADC治療薬の価格予測：タイプ別 (2026-2031)

第5章 市場規模：用途別

• 世界の販売：用途別
  • 世界の乳がんADC治療薬の販売実績：用途別 (2020-2025)
  • 世界の乳がんADC治療薬の販売予測：用途別 (2026-2031)
  • 世界の乳がんADC治療薬の販売市場シェア：用途別 (2020-2031)
• 世界の収益：用途別
  • 世界の乳がんADC治療薬の収益実績：用途別 (2020-2025)
  • 世界の乳がんADC治療薬の収益予測：用途別 (2026-2031)
  • 世界の乳がんADC治療薬の収益市場シェア：用途別 (2020-2031)
• 世界の価格：用途別
  • 世界の乳がんADC治療薬 価格：用途別 (2020-2025)
  • 世界の乳がんADC治療薬の価格予測：用途別 (2026-2031)

第6章 米国・カナダ

• 米国・カナダ 市場規模：タイプ別
  • 米国・カナダ 乳がんADC治療薬 販売：タイプ別 (2020-2031)
  • 米国・カナダ 乳がんADC治療薬 収益：タイプ別 (2020-2031)
• 米国・カナダ 市場規模：用途別
  • 米国・カナダ 乳がんADC治療薬 販売：用途別 (2020-2031)
  • 米国・カナダ 乳がんADC治療薬 収益：用途別 (2020-2031)
• 米国・カナダ 市場規模：国別
  • 米国・カナダ 乳がんADC治療薬の収益：国別: 2020 VS 2024 VS 2031
  • 米国・カナダ 乳がんADC治療薬の収益：国別 (2020-2031)
  • 米国・カナダ 乳がんADC治療薬の販売：国別 (2020-2031)
  • US
  • カナダ

第7章 欧州

• 欧州の市場規模：タイプ別
  • 欧州の乳がんADC治療薬 販売：タイプ別 (2020-2031)
  • 欧州の乳がんADC治療薬 収益：タイプ別 (2020-2031)
• 欧州の市場規模：用途別
  • 欧州の乳がんADC治療薬 販売：用途別 (2020-2031)
  • 欧州の乳がんADC治療薬 収益：用途別 (2020-2031)
• 欧州の市場規模：国別
  • 欧州の乳がんADC治療薬の収益：国別: 2020 VS 2024 VS 2031
  • 欧州の乳がんADC治療薬の販売：国別 (2020-2031)
  • 欧州の乳がんADC治療薬の収益：国別 (2020-2031)
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • ロシア

第8章 中国

• 中国の市場規模：タイプ別
  • 中国の乳がんADC治療薬 販売：タイプ別 (2020-2031)
  • 中国の乳がんADC治療薬 収益：タイプ別 (2020-2031)
• 中国の市場規模：用途別
  • 中国の乳がんADC治療薬 販売：用途別 (2020-2031)
  • 中国の乳がんADC治療薬 収益：用途別 (2020-2031)

第9章 アジア（中国を除く）

• アジア地域 市場規模：タイプ別
  • アジア地域 乳がんADC治療薬 販売：タイプ別 (2020-2031)
  • アジア地域 乳がんADC治療薬 収益：タイプ別 (2020-2031)
• アジア地域 市場規模：用途別
  • アジア地域 乳がんADC治療薬 販売：用途別 (2020-2031)
  • アジア地域 乳がんADC治療薬 収益：用途別 (2020-2031)
• アジア地域 市場規模：地域別
  • アジア地域 乳がんADC治療薬 収益：地域別: 2020 VS 2024 VS 2031
  • アジア地域 乳がんADC治療薬 収益：地域別 (2020-2031)
  • アジア地域 乳がんADC治療薬 販売：地域別 (2020-2031)
  • 日本
  • 韓国
  • 台湾
  • 東南アジア
  • インド
  • オーストラリア

第10章 中東, アフリカ ・ラテンアメリカ

• 中東, アフリカ ・ラテンアメリカの市場規模：タイプ別
  • 中東, アフリカ ・ラテンアメリカの乳がんADC治療薬 販売：タイプ別 (2020-2031)
  • 中東, アフリカ ・ラテンアメリカの乳がんADC治療薬 収益：タイプ別 (2020-2031)
• 中東, アフリカ ・ラテンアメリカの市場規模：用途別
  • 中東, アフリカ ・ラテンアメリカの乳がんADC治療薬 販売：用途別 (2020-2031)
  • 中東, アフリカ ・ラテンアメリカの乳がんADC治療薬 収益：用途別 (2020-2031)
• 中東, アフリカ ・ラテンアメリカの市場規模：国別
  • 中東, アフリカ ・ラテンアメリカの乳がんADC治療薬の収益：国別: 2020 VS 2024 VS 2031
  • 中東, アフリカ ・ラテンアメリカの乳がんADC治療薬の収益：国別 (2020-2031)
  • 中東, アフリカ ・ラテンアメリカの乳がんADC治療薬の販売：国別 (2020-2031)
  • ブラジル
  • メキシコ
  • トルコ
  • イスラエル
  • 湾岸協力理事会諸国

第11章 企業プロファイル

• Pfizer
• Genentech
• AstraZeneca
• Daiichi
• Gilead

第12章 業界チェーンと販売チャネルの分析

• 乳がんADC治療薬 業界チェーン分析
• 乳がんADC治療薬 主要原材料
  • 主要原材料
  • 原材料の主要サプライヤー
• 乳がんADC治療薬 生産形態とプロセス
• 乳がんADC治療薬 販売およびマーケティング
  • 乳がんADC治療薬 販売チャネルs
  • 乳がんADC治療薬 卸業者
• 乳がんADC治療薬 顧客

第13章 乳がんADC治療薬 市場動向

• 乳がんADC治療薬 業界動向
• 乳がんADC治療薬 市場の促進要因
• 乳がんADC治療薬 市場の課題
• 乳がんADC治療薬 市場の抑制要因

第14章 主な調査結果 世界の乳がんADC治療薬の主な市場調査結果

第15章 付録

List of Tables

Table 1. Global Breast Cancer ADC Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Major Manufacturers of First-generation ADC Drugs

Table 3. Major Manufacturers of Second-generation ADC Drugs

Table 4. Major Manufacturers of Third-generation ADC Drugs

Table 5. Global Breast Cancer ADC Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 6. Global Breast Cancer ADC Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 7. Global Revenue by Region (2020-2025) & (US$ Million)

Table 8. Global Revenue Market Share by Region (2020-2031)

Table 9. Global Breast Cancer ADC Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)

Table 10. Global Breast Cancer ADC Drugs Sales by Region (2020-2031) & (K Units)

Table 11. Global Sales Market Share by Region (2020-2031)

Table 12. Global Breast Cancer ADC Drugs Sales by Manufacturers (2020-2025) & (K Units)

Table 13. Global Breast Cancer ADC Drugs Sales Share by Manufacturers (2020-2025)

Table 14. Global Breast Cancer ADC Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 15. Global Breast Cancer ADC Drugs Revenue Market Share by Manufacturers (2020-2025)

Table 16. Global Key Players of Breast Cancer ADC Drugs, Industry Ranking, 2023 VS 2024 VS 2024

Table 17. Breast Cancer ADC Drugs Price by Manufacturers (2020-2025) & (US$/Unit)

Table 18. Global Breast Cancer ADC Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 19. Global Breast Cancer ADC Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Breast Cancer ADC Drugs as of 2024)

Table 20. Global Key Manufacturers of Breast Cancer ADC Drugs, Manufacturing Base Distribution and Headquarters

Table 21. Global Key Manufacturers of Breast Cancer ADC Drugs, Product Offered and Application

Table 22. Global Key Manufacturers of Breast Cancer ADC Drugs, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Breast Cancer ADC Drugs Sales by Type (2020-2025) & (K Units)

Table 25. Global Breast Cancer ADC Drugs Sales by Type (2026-2031) & (K Units)

Table 26. Global Sales Share by Type (2020-2031)

Table 27. Global Breast Cancer ADC Drugs Revenue by Type (2020-2025) & (US$ Million)

Table 28. Global Breast Cancer ADC Drugs Revenue by Type (2026-2031) & (US$ Million)

Table 29. Global Revenue Share by Type (2020-2031)

Table 30. Breast Cancer ADC Drugs Price by Type (2020-2025) & (US$/Unit)

Table 31. Global Breast Cancer ADC Drugs Price Forecast by Type (2026-2031) & (US$/Unit)

Table 32. Global Breast Cancer ADC Drugs Sales by Application (2020-2025) & (K Units)

Table 33. Global Breast Cancer ADC Drugs Sales by Application (2026-2031) & (K Units)

Table 34. Global Sales Share by Application (2020-2031)

Table 35. Global Breast Cancer ADC Drugs Revenue by Application (2020-2025) & (US$ Million)

Table 36. Global Breast Cancer ADC Drugs Revenue by Application (2026-2031) & (US$ Million)

Table 37. Global Revenue Share by Application (2020-2031)

Table 38. Breast Cancer ADC Drugs Price by Application (2020-2025) & (US$/Unit)

Table 39. Global Breast Cancer ADC Drugs Price Forecast by Application (2026-2031) & (US$/Unit)

Table 40. US & Canada Sales by Type (2020-2031) & (K Units)

Table 41. US & Canada Revenue by Type (2020-2031) & (US$ Million)

Table 42. US & Canada Sales by Application (2020-2031) & (K Units)

Table 43. US & Canada Revenue by Application (2020-2031) & (US$ Million)

Table 44. US & Canada Breast Cancer ADC Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 45. US & Canada Revenue by Country (2020-2031) & (US$ Million)

Table 46. US & Canada Sales by Country (2020-2031) & (K Units)

Table 47. Europe Sales by Type (2020-2031) & (K Units)

Table 48. Europe Revenue by Type (2020-2031) & (US$ Million)

Table 49. Europe Sales by Application (2020-2031) & (K Units)

Table 50. Europe Revenue by Application (2020-2031) & (US$ Million)

Table 51. Europe Breast Cancer ADC Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 52. Europe Sales by Country (2020-2031) & (K Units)

Table 53. Europe Revenue by Country (2020-2031) & (US$ Million)

Table 54. China Sales by Type (2020-2031) & (K Units)

Table 55. China Revenue by Type (2020-2031) & (US$ Million)

Table 56. China Sales by Application (2020-2031) & (K Units)

Table 57. China Revenue by Application (2020-2031) & (US$ Million)

Table 58. Asia Sales by Type (2020-2031) & (K Units)

Table 59. Asia Revenue by Type (2020-2031) & (US$ Million)

Table 60. Asia Sales by Application (2020-2031) & (K Units)

Table 61. Asia Revenue by Application (2020-2031) & (US$ Million)

Table 62. Asia Breast Cancer ADC Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 63. Asia Revenue by Region (2020-2031) & (US$ Million)

Table 64. Asia Sales by Region (2020-2031) & (K Units)

Table 65. Middle East, Africa and Latin America Sales by Type (2020-2031) & (K Units)

Table 66. Middle East, Africa and Latin America Revenue by Type (2020-2031) & (US$ Million)

Table 67. Middle East, Africa and Latin America Sales by Application (2020-2031) & (K Units)

Table 68. Middle East, Africa and Latin America Revenue by Application (2020-2031) & (US$ Million)

Table 69. Middle East, Africa and Latin America Breast Cancer ADC Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 70. Middle East, Africa and Latin America Revenue by Country (2020-2031) & (US$ Million)

Table 71. Middle East, Africa and Latin America Sales by Country (2020-2031) & (K Units)

Table 72. Pfizer Company Information

Table 73. Pfizer Description and Major Businesses

Table 74. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 75. Pfizer Product Model Numbers, Pictures, Descriptions and Specifications

Table 76. Pfizer Recent Developments

Table 77. Genentech Company Information

Table 78. Genentech Description and Major Businesses

Table 79. Genentech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 80. Genentech Product Model Numbers, Pictures, Descriptions and Specifications

Table 81. Genentech Recent Developments

Table 82. AstraZeneca Company Information

Table 83. AstraZeneca Description and Major Businesses

Table 84. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 85. AstraZeneca Product Model Numbers, Pictures, Descriptions and Specifications

Table 86. AstraZeneca Recent Developments

Table 87. Daiichi Company Information

Table 88. Daiichi Description and Major Businesses

Table 89. Daiichi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. Daiichi Product Model Numbers, Pictures, Descriptions and Specifications

Table 91. Daiichi Recent Developments

Table 92. Gilead Company Information

Table 93. Gilead Description and Major Businesses

Table 94. Gilead Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 95. Gilead Product Model Numbers, Pictures, Descriptions and Specifications

Table 96. Gilead Recent Developments

Table 97. Key Raw Materials Lists

Table 98. Raw Materials Key Suppliers Lists

Table 99. Distributors List

Table 100. Customers List

Table 101. Market Trends

Table 102. Market Drivers

Table 103. Market Challenges

Table 104. Market Restraints

Table 105. Research Programs/Design for This Report

Table 106. Key Data Information from Secondary Sources

Table 107. Key Data Information from Primary Sources

List of Figures

Figure 1. Breast Cancer ADC Drugs Product Picture

Figure 2. Global Breast Cancer ADC Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global Breast Cancer ADC Drugs Market Share by Type: 2024 & 2031

Figure 4. First-generation ADC Drugs Product Picture

Figure 5. Second-generation ADC Drugs Product Picture

Figure 6. Third-generation ADC Drugs Product Picture

Figure 7. Global Breast Cancer ADC Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 8. Global Breast Cancer ADC Drugs Market Share by Application: 2024 & 2031

Figure 9. Non-invasive Cancer

Figure 10. Invasive Cancer

Figure 11. Breast Cancer ADC Drugs Report Years Considered

Figure 12. Global Breast Cancer ADC Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 14. Global Breast Cancer ADC Drugs Revenue by Region (2020-2031) (US$ Million)

Figure 15. Global Breast Cancer ADC Drugs Revenue Market Share by Region in Percentage: 2024 Versus 2031

Figure 16. Global Breast Cancer ADC Drugs Revenue Market Share by Region (2020-2031)

Figure 17. Global Breast Cancer ADC Drugs Sales (2020-2031) & (K Units)

Figure 18. Global Breast Cancer ADC Drugs Sales (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)

Figure 19. Global Breast Cancer ADC Drugs Sales Market Share by Region (2020-2031)

Figure 20. US & Canada Breast Cancer ADC Drugs Sales YoY (2020-2031) & (K Units)

Figure 21. US & Canada Breast Cancer ADC Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 22. Europe Breast Cancer ADC Drugs Sales YoY (2020-2031) & (K Units)

Figure 23. Europe Breast Cancer ADC Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 24. China Breast Cancer ADC Drugs Sales YoY (2020-2031) & (K Units)

Figure 25. China Breast Cancer ADC Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 26. Asia (excluding China) Breast Cancer ADC Drugs Sales YoY (2020-2031) & (K Units)

Figure 27. Asia (excluding China) Breast Cancer ADC Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 28. Middle East, Africa and Latin America Breast Cancer ADC Drugs Sales YoY (2020-2031) & (K Units)

Figure 29. Middle East, Africa and Latin America Breast Cancer ADC Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 30. Global Breast Cancer ADC Drugs Sales Share by Manufacturers (2024)

Figure 31. The Breast Cancer ADC Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2024

Figure 32. Global Breast Cancer ADC Drugs Revenue Share by Manufacturers (2024)

Figure 33. The Top 5 and 10 Largest Manufacturers of Breast Cancer ADC Drugs in the World: Market Share by Breast Cancer ADC Drugs Revenue in 2024

Figure 34. Global Breast Cancer ADC Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 35. Global Breast Cancer ADC Drugs Sales Market Share by Type (2020-2031)

Figure 36. Global Breast Cancer ADC Drugs Revenue Market Share by Type (2020-2031)

Figure 37. Global Breast Cancer ADC Drugs Sales Market Share by Application (2020-2031)

Figure 38. Global Breast Cancer ADC Drugs Revenue Market Share by Application (2020-2031)

Figure 39. US & Canada Breast Cancer ADC Drugs Sales Market Share by Type (2020-2031)

Figure 40. US & Canada Breast Cancer ADC Drugs Revenue Market Share by Type (2020-2031)

Figure 41. US & Canada Breast Cancer ADC Drugs Sales Market Share by Application (2020-2031)

Figure 42. US & Canada Breast Cancer ADC Drugs Revenue Market Share by Application (2020-2031)

Figure 43. US & Canada Breast Cancer ADC Drugs Revenue Share by Country (2020-2031)

Figure 44. US & Canada Breast Cancer ADC Drugs Sales Share by Country (2020-2031)

Figure 45. US Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 46. Canada Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 47. Europe Breast Cancer ADC Drugs Sales Market Share by Type (2020-2031)

Figure 48. Europe Breast Cancer ADC Drugs Revenue Market Share by Type (2020-2031)

Figure 49. Europe Breast Cancer ADC Drugs Sales Market Share by Application (2020-2031)

Figure 50. Europe Breast Cancer ADC Drugs Revenue Market Share by Application (2020-2031)

Figure 51. Europe Breast Cancer ADC Drugs Sales Share by Country (2020-2031)

Figure 52. Europe Breast Cancer ADC Drugs Revenue Share by Country (2020-2031)

Figure 53. Germany Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 54. France Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 55. U.K. Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 56. Italy Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 57. Russia Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 58. China Breast Cancer ADC Drugs Sales Market Share by Type (2020-2031)

Figure 59. China Breast Cancer ADC Drugs Revenue Market Share by Type (2020-2031)

Figure 60. China Breast Cancer ADC Drugs Sales Market Share by Application (2020-2031)

Figure 61. China Breast Cancer ADC Drugs Revenue Market Share by Application (2020-2031)

Figure 62. Asia Breast Cancer ADC Drugs Sales Market Share by Type (2020-2031)

Figure 63. Asia Breast Cancer ADC Drugs Revenue Market Share by Type (2020-2031)

Figure 64. Asia Breast Cancer ADC Drugs Sales Market Share by Application (2020-2031)

Figure 65. Asia Breast Cancer ADC Drugs Revenue Market Share by Application (2020-2031)

Figure 66. Asia Breast Cancer ADC Drugs Revenue Share by Region (2020-2031)

Figure 67. Asia Breast Cancer ADC Drugs Sales Share by Region (2020-2031)

Figure 68. Japan Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 69. South Korea Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 70. China Taiwan Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 71. Southeast Asia Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 72. India Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 73. Australia Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 74. Middle East, Africa and Latin America Breast Cancer ADC Drugs Sales Market Share by Type (2020-2031)

Figure 75. Middle East, Africa and Latin America Breast Cancer ADC Drugs Revenue Market Share by Type (2020-2031)

Figure 76. Middle East, Africa and Latin America Breast Cancer ADC Drugs Sales Market Share by Application (2020-2031)

Figure 77. Middle East, Africa and Latin America Breast Cancer ADC Drugs Revenue Market Share by Application (2020-2031)

Figure 78. Middle East, Africa and Latin America Breast Cancer ADC Drugs Revenue Share by Country (2020-2031)

Figure 79. Middle East, Africa and Latin America Breast Cancer ADC Drugs Sales Share by Country (2020-2031)

Figure 80. Brazil Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 81. Mexico Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 82. Turkey Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 83. Israel Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 84. GCC Countries Breast Cancer ADC Drugs Revenue (2020-2031) & (US$ Million)

Figure 85. Value Chain

Figure 86. Breast Cancer ADC Drugs Production Process

Figure 87. Channels of Distribution (Direct Vs Distribution)

Figure 88. Bottom-up and Top-down Approaches for This Report

Figure 89. Data Triangulation

Figure 90. Key Executives Interviewed

This research report focuses on the Breast Cancer ADC Drugs Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

• 1.1 Breast Cancer ADC Drugs Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global Breast Cancer ADC Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031
  • 1.2.2 First-generation ADC Drugs
  • 1.2.3 Second-generation ADC Drugs
  • 1.2.4 Third-generation ADC Drugs
• 1.3 Market by Application
  • 1.3.1 Global Breast Cancer ADC Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031
  • 1.3.2 Non-invasive Cancer
  • 1.3.3 Invasive Cancer
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Executive Summary

• 2.1 Global Breast Cancer ADC Drugs Revenue Estimates and Forecasts 2020-2031
• 2.2 Global Revenue by Region
  • 2.2.1 Global Breast Cancer ADC Drugs Revenue by Region: 2020 VS 2024 VS 2031
  • 2.2.2 Global Breast Cancer ADC Drugs Revenue by Region (2020-2031)
  • 2.2.3 Global Breast Cancer ADC Drugs Revenue Market Share by Region (2020-2031)
• 2.3 Global Breast Cancer ADC Drugs Sales Estimates and Forecasts 2020-2031
• 2.4 Global Sales by Region
  • 2.4.1 Global Breast Cancer ADC Drugs Sales by Region: 2020 VS 2024 VS 2031
  • 2.4.2 Global Breast Cancer ADC Drugs Sales by Region (2020-2031)
  • 2.4.3 Global Breast Cancer ADC Drugs Sales Market Share by Region (2020-2031)
• 2.5 US & Canada
• 2.6 Europe
• 2.7 China
• 2.8 Asia (excluding China)
• 2.9 Middle East, Africa and Latin America

3 Competition by Manufacturers

• 3.1 Global Sales by Manufacturers
  • 3.1.1 Global Breast Cancer ADC Drugs Sales by Manufacturers (2020-2025)
  • 3.1.2 Global Breast Cancer ADC Drugs Sales Market Share by Manufacturers (2020-2025)
  • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Breast Cancer ADC Drugs in 2024
• 3.2 Global Revenue by Manufacturers
  • 3.2.1 Global Breast Cancer ADC Drugs Revenue by Manufacturers (2020-2025)
  • 3.2.2 Global Breast Cancer ADC Drugs Revenue Market Share by Manufacturers (2020-2025)
  • 3.2.3 Global Top 10 and Top 5 Companies by Breast Cancer ADC Drugs Revenue in 2024
• 3.3 Global Key Players of Breast Cancer ADC Drugs, Industry Ranking, 2023 VS 2024
• 3.4 Global Breast Cancer ADC Drugs Sales Price by Manufacturers (2020-2025)
• 3.5 Analysis of Competitive Landscape
  • 3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.5.2 Global Breast Cancer ADC Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.6 Global Key Manufacturers of Breast Cancer ADC Drugs, Manufacturing Base Distribution and Headquarters
• 3.7 Global Key Manufacturers of Breast Cancer ADC Drugs, Product Offered and Application
• 3.8 Global Key Manufacturers of Breast Cancer ADC Drugs, Date of Enter into This Industry
• 3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Global Sales by Type
  • 4.1.1 Global Breast Cancer ADC Drugs Historical Sales by Type (2020-2025)
  • 4.1.2 Global Breast Cancer ADC Drugs Forecasted Sales by Type (2026-2031)
  • 4.1.3 Global Breast Cancer ADC Drugs Sales Market Share by Type (2020-2031)
• 4.2 Global Revenue by Type
  • 4.2.1 Global Breast Cancer ADC Drugs Historical Revenue by Type (2020-2025)
  • 4.2.2 Global Breast Cancer ADC Drugs Forecasted Revenue by Type (2026-2031)
  • 4.2.3 Global Breast Cancer ADC Drugs Revenue Market Share by Type (2020-2031)
• 4.3 Global Price by Type
  • 4.3.1 Global Breast Cancer ADC Drugs Price by Type (2020-2025)
  • 4.3.2 Global Breast Cancer ADC Drugs Price Forecast by Type (2026-2031)

5 Market Size by Application

• 5.1 Global Sales by Application
  • 5.1.1 Global Breast Cancer ADC Drugs Historical Sales by Application (2020-2025)
  • 5.1.2 Global Breast Cancer ADC Drugs Forecasted Sales by Application (2026-2031)
  • 5.1.3 Global Breast Cancer ADC Drugs Sales Market Share by Application (2020-2031)
• 5.2 Global Revenue by Application
  • 5.2.1 Global Breast Cancer ADC Drugs Historical Revenue by Application (2020-2025)
  • 5.2.2 Global Breast Cancer ADC Drugs Forecasted Revenue by Application (2026-2031)
  • 5.2.3 Global Breast Cancer ADC Drugs Revenue Market Share by Application (2020-2031)
• 5.3 Global Price by Application
  • 5.3.1 Global Breast Cancer ADC Drugs Price by Application (2020-2025)
  • 5.3.2 Global Breast Cancer ADC Drugs Price Forecast by Application (2026-2031)

6 US & Canada

• 6.1 US & Canada Market Size by Type
  • 6.1.1 US & Canada Breast Cancer ADC Drugs Sales by Type (2020-2031)
  • 6.1.2 US & Canada Breast Cancer ADC Drugs Revenue by Type (2020-2031)
• 6.2 US & Canada Market Size by Application
  • 6.2.1 US & Canada Breast Cancer ADC Drugs Sales by Application (2020-2031)
  • 6.2.2 US & Canada Breast Cancer ADC Drugs Revenue by Application (2020-2031)
• 6.3 US & Canada Market Size by Country
  • 6.3.1 US & Canada Breast Cancer ADC Drugs Revenue by Country: 2020 VS 2024 VS 2031
  • 6.3.2 US & Canada Breast Cancer ADC Drugs Revenue by Country (2020-2031)
  • 6.3.3 US & Canada Breast Cancer ADC Drugs Sales by Country (2020-2031)
  • 6.3.4 US
  • 6.3.5 Canada

7 Europe

• 7.1 Europe Market Size by Type
  • 7.1.1 Europe Breast Cancer ADC Drugs Sales by Type (2020-2031)
  • 7.1.2 Europe Breast Cancer ADC Drugs Revenue by Type (2020-2031)
• 7.2 Europe Market Size by Application
  • 7.2.1 Europe Breast Cancer ADC Drugs Sales by Application (2020-2031)
  • 7.2.2 Europe Breast Cancer ADC Drugs Revenue by Application (2020-2031)
• 7.3 Europe Market Size by Country
  • 7.3.1 Europe Breast Cancer ADC Drugs Revenue by Country: 2020 VS 2024 VS 2031
  • 7.3.2 Europe Breast Cancer ADC Drugs Sales by Country (2020-2031)
  • 7.3.3 Europe Breast Cancer ADC Drugs Revenue by Country (2020-2031)
  • 7.3.4 Germany
  • 7.3.5 France
  • 7.3.6 U.K.
  • 7.3.7 Italy
  • 7.3.8 Russia

8 China

• 8.1 China Market Size by Type
  • 8.1.1 China Breast Cancer ADC Drugs Sales by Type (2020-2031)
  • 8.1.2 China Breast Cancer ADC Drugs Revenue by Type (2020-2031)
• 8.2 China Market Size by Application
  • 8.2.1 China Breast Cancer ADC Drugs Sales by Application (2020-2031)
  • 8.2.2 China Breast Cancer ADC Drugs Revenue by Application (2020-2031)

9 Asia (excluding China)

• 9.1 Asia Market Size by Type
  • 9.1.1 Asia Breast Cancer ADC Drugs Sales by Type (2020-2031)
  • 9.1.2 Asia Breast Cancer ADC Drugs Revenue by Type (2020-2031)
• 9.2 Asia Market Size by Application
  • 9.2.1 Asia Breast Cancer ADC Drugs Sales by Application (2020-2031)
  • 9.2.2 Asia Breast Cancer ADC Drugs Revenue by Application (2020-2031)
• 9.3 Asia Market Size by Region
  • 9.3.1 Asia Breast Cancer ADC Drugs Revenue by Region: 2020 VS 2024 VS 2031
  • 9.3.2 Asia Breast Cancer ADC Drugs Revenue by Region (2020-2031)
  • 9.3.3 Asia Breast Cancer ADC Drugs Sales by Region (2020-2031)
  • 9.3.4 Japan
  • 9.3.5 South Korea
  • 9.3.6 China Taiwan
  • 9.3.7 Southeast Asia
  • 9.3.8 India
  • 9.3.9 Australia

10 Middle East, Africa and Latin America

• 10.1 Middle East, Africa and Latin America Market Size by Type
  • 10.1.1 Middle East, Africa and Latin America Breast Cancer ADC Drugs Sales by Type (2020-2031)
  • 10.1.2 Middle East, Africa and Latin America Breast Cancer ADC Drugs Revenue by Type (2020-2031)
• 10.2 Middle East, Africa and Latin America Market Size by Application
  • 10.2.1 Middle East, Africa and Latin America Breast Cancer ADC Drugs Sales by Application (2020-2031)
  • 10.2.2 Middle East, Africa and Latin America Breast Cancer ADC Drugs Revenue by Application (2020-2031)
• 10.3 Middle East, Africa and Latin America Market Size by Country
  • 10.3.1 Middle East, Africa and Latin America Breast Cancer ADC Drugs Revenue by Country: 2020 VS 2024 VS 2031
  • 10.3.2 Middle East, Africa and Latin America Breast Cancer ADC Drugs Revenue by Country (2020-2031)
  • 10.3.3 Middle East, Africa and Latin America Breast Cancer ADC Drugs Sales by Country (2020-2031)
  • 10.3.4 Brazil
  • 10.3.5 Mexico
  • 10.3.6 Turkey
  • 10.3.7 Israel
  • 10.3.8 GCC Countries

11 Corporate Profile

• 11.1 Pfizer
  • 11.1.1 Pfizer Company Information
  • 11.1.2 Pfizer Overview
  • 11.1.3 Pfizer Breast Cancer ADC Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.1.4 Pfizer Breast Cancer ADC Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.1.5 Pfizer Recent Developments
• 11.2 Genentech
  • 11.2.1 Genentech Company Information
  • 11.2.2 Genentech Overview
  • 11.2.3 Genentech Breast Cancer ADC Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.2.4 Genentech Breast Cancer ADC Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.2.5 Genentech Recent Developments
• 11.3 AstraZeneca
  • 11.3.1 AstraZeneca Company Information
  • 11.3.2 AstraZeneca Overview
  • 11.3.3 AstraZeneca Breast Cancer ADC Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.3.4 AstraZeneca Breast Cancer ADC Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.3.5 AstraZeneca Recent Developments
• 11.4 Daiichi
  • 11.4.1 Daiichi Company Information
  • 11.4.2 Daiichi Overview
  • 11.4.3 Daiichi Breast Cancer ADC Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.4.4 Daiichi Breast Cancer ADC Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.4.5 Daiichi Recent Developments
• 11.5 Gilead
  • 11.5.1 Gilead Company Information
  • 11.5.2 Gilead Overview
  • 11.5.3 Gilead Breast Cancer ADC Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
  • 11.5.4 Gilead Breast Cancer ADC Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.5.5 Gilead Recent Developments

12 Industry Chain and Sales Channels Analysis

• 12.1 Breast Cancer ADC Drugs Industry Chain Analysis
• 12.2 Breast Cancer ADC Drugs Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 Breast Cancer ADC Drugs Production Mode & Process
• 12.4 Breast Cancer ADC Drugs Sales and Marketing
  • 12.4.1 Breast Cancer ADC Drugs Sales Channels
  • 12.4.2 Breast Cancer ADC Drugs Distributors
• 12.5 Breast Cancer ADC Drugs Customers

13 Breast Cancer ADC Drugs Market Dynamics

• 13.1 Breast Cancer ADC Drugs Industry Trends
• 13.2 Breast Cancer ADC Drugs Market Drivers
• 13.3 Breast Cancer ADC Drugs Market Challenges
• 13.4 Breast Cancer ADC Drugs Market Restraints

14 Key Findings in the Global Breast Cancer ADC Drugs Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Author Details
• 15.3 Disclaimer